Cover Image
市場調查報告書

末期腎臟疾病(DSRD):開發中產品分析

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257819
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
末期腎臟疾病(DSRD):開發中產品分析 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 65 Pages
簡介

所謂末期腎臟疾病(DSRD),是指腎臟的功能(幾乎)完全喪失的狀態。主要的症狀為,排尿不全和倦怠感,頭痛,食慾不振,噁心嘔吐,骨頭疼痛,意識混濁,集中力降低等。主要風險因素有多發性囊胞腎臟疾病和亞伯氏症候群,間質性腎炎,部分自體免疫障礙(狼瘡等)。還有主要治療方法為透析、腎臟移植等。

本報告提供全球各國治療末期腎臟疾病(DSRD)所用的開發中產品之開發情形相關分析,提供您開發中產品的開發·上市最新趨勢,臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查資訊。

目錄

簡介

  • 分析範圍

末期腎臟疾病概要

治療藥的開發

  • 末期腎臟疾病開發中產品:概要

各企業開發中的末期腎臟疾病治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

末期腎臟疾病治療藥:開發中的產品一覽(各企業)

末期腎臟疾病開發治療藥的企業

  • Acceleron Pharma, Inc.
  • Bayer AG
  • BioAegis Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Prolong Pharmaceuticals, LLC

末期腎臟疾病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

末期腎臟疾病治療藥:開發中產品的最新趨勢

末期腎臟疾病治療藥:暫停的計劃

末期腎臟疾病治療藥:開發中止的產品

末期腎臟疾病相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8754IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2016, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 1, 4 and 2 respectively.End-Stage Kidney Disease.

End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Overview
  • Therapeutics Development
    • Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics under Development by Companies
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Products under Development by Companies
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
    • Acceleron Pharma Inc
    • BioAegis Therapeutics Inc
    • BLR Bio LLC
    • Bristol-Myers Squibb Company
    • CTI BioPharma Corp
    • F. Hoffmann-La Roche Ltd
    • Prolong Pharmaceuticals LLC
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BLR-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • calcium succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obinutuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pacritinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sanguinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotatercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014
      • Apr 23, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis
      • Mar 17, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting
      • Dec 18, 2013: Acceleron Earns $7 Million Milestone Payment for Celgene's Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Acceleron Pharma Inc, H2 2016
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, H2 2016
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BLR Bio LLC, H2 2016
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by CTI BioPharma Corp, H2 2016
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Prolong Pharmaceuticals LLC, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H2 2016
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top